Two-year follow-up data on 20 patients with severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID) who received Orchard Therapeutics' (NASDAQ:ORTX) OTL-101, an autologous hematopoietic stem cell gene therapy, showed a positive effect. At month 24, the overall survival (OS) rate was 100% as was event-free survival (EFS). OS was 12% better than hematopoietic stem cell transplantation (HSCT) while EFS was 44% better Source: Seeking Alpha 22/2/2019